Loading clinical trials...
Loading clinical trials...
This is a Phase 2 study to see if an investigational drug, ANG1005, can shrink tumor cells in patients with high-grade glioma. Another purpose of this study is to assess the efficacy, safety, tolerabi...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Angiochem Inc
NCT05765812 · Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, Astrocytoma, Grade III
NCT06814496 · Melanoma, Medullary Thyroid Cancer, and more
NCT06039709 · Recurrent Glioblastoma, Glioblastoma Multiforme, and more
NCT07539441 · Central Nervous System Tumors, Glioma
NCT04065776 · Glioma, Pilocytic Astrocytoma, and more
Moores UC San Diego Cancer Center
La Jolla, California
Northwestern University
Chicago, Illinois
Massachusetts General Hospital
Boston, Massachusetts
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions